Illumina acquire GRAIL (maybe)
So Illumina are pushing forward with their GRAIL acquisition. It seems like a good time to review what (little) I know of the early stage cancer detection market and how it plays into sequencing.
GRAILs initial thesis was that they’d sequence cfDNA (cell free DNA, shed from cells in blood) at very high depth. Some small fraction of these fragments w…